376 related articles for article (PubMed ID: 15864313)
1. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
[TBL] [Abstract][Full Text] [Related]
2. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Sarkar S; Rubinsztein DC
Hum Mol Genet; 2006 Jan; 15(1):23-31. PubMed ID: 16311254
[TBL] [Abstract][Full Text] [Related]
3. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.
Davies JE; Berger Z; Rubinsztein DC
Int J Biochem Cell Biol; 2006; 38(9):1457-62. PubMed ID: 16530457
[TBL] [Abstract][Full Text] [Related]
4. [Oculopharyngeal muscular dystrophy: study of patients from seven Spanish families with different GCG expansions in PABP2 gene].
Pou Serradell A; Lloreta Trull J; Corominas Torres JM; Hammouda EH; Urtizberea JA; Richard P; Brais B
Neurologia; 2004 Jun; 19(5):239-47. PubMed ID: 15150706
[TBL] [Abstract][Full Text] [Related]
5. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
[TBL] [Abstract][Full Text] [Related]
6. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rose C; Sarkar S; Rubinsztein DC
Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
[TBL] [Abstract][Full Text] [Related]
7. Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy.
Messaed C; Dion PA; Abu-Baker A; Rochefort D; Laganiere J; Brais B; Rouleau GA
Neurobiol Dis; 2007 Jun; 26(3):546-57. PubMed ID: 17418585
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel mutation in a Korean patient with oculopharyngeal muscular dystrophy.
Bae JS; Ki CS; Kim JW; Kim BJ
J Clin Neurosci; 2007 Jan; 14(1):89-92. PubMed ID: 17138075
[TBL] [Abstract][Full Text] [Related]
9. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.
Verheesen P; de Kluijver A; van Koningsbruggen S; de Brij M; de Haard HJ; van Ommen GJ; van der Maarel SM; Verrips CT
Hum Mol Genet; 2006 Jan; 15(1):105-11. PubMed ID: 16319127
[TBL] [Abstract][Full Text] [Related]
10. Oculopharyngeal muscular dystrophy.
Brais B; Rouleau GA; Bouchard JP; Fardeau M; Tomé FM
Semin Neurol; 1999; 19(1):59-66. PubMed ID: 10711989
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
[TBL] [Abstract][Full Text] [Related]
12. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.
Rivera D; Mejia-Lopez H; Pompa-Mera EN; Villanueva-Mendoza C; Nava-Castañeda A; Garnica-Hayashi L; Cuevas-Covarrubias S; Zenteno JC
Br J Ophthalmol; 2008 Jul; 92(7):998-1002. PubMed ID: 18577654
[TBL] [Abstract][Full Text] [Related]
13. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.
van der Sluijs BM; van Engelen BG; Hoefsloot LH
Hum Mutat; 2003 May; 21(5):553. PubMed ID: 12673802
[TBL] [Abstract][Full Text] [Related]
14. [Preferential distal muscle involvement in case of oculopharyngeal muscular dystrophy with (GCG) 13 expansion].
Nakashima D; Nakajima H; Ishida S; Sugino M; Kimura F; Hanafusa T
Rinsho Shinkeigaku; 2003 Sep; 43(9):560-3. PubMed ID: 14727564
[TBL] [Abstract][Full Text] [Related]
15. Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice.
Dion P; Shanmugam V; Gaspar C; Messaed C; Meijer I; Toulouse A; Laganiere J; Roussel J; Rochefort D; Laganiere S; Allen C; Karpati G; Bouchard JP; Brais B; Rouleau GA
Neurobiol Dis; 2005 Apr; 18(3):528-36. PubMed ID: 15755680
[TBL] [Abstract][Full Text] [Related]
16. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation.
Périé S; Mamchaoui K; Mouly V; Blot S; Bouazza B; Thornell LE; St Guily JL; Butler-Browne G
Neuromuscul Disord; 2006 Nov; 16(11):770-81. PubMed ID: 17005403
[TBL] [Abstract][Full Text] [Related]
17. Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1.
Lodderstedt G; Hess S; Hause G; Scheuermann T; Scheibel T; Schwarz E
FEBS J; 2007 Jan; 274(2):346-55. PubMed ID: 17229142
[TBL] [Abstract][Full Text] [Related]
18. A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy.
Gürtler N; Plasilova M; Podvinec M; Boesch N; Müller H; Heinimann K
Laryngoscope; 2006 Jan; 116(1):111-4. PubMed ID: 16481821
[TBL] [Abstract][Full Text] [Related]
19. Oculopharyngeal muscular dystrophy: phenotypic and genotypic characteristics of 9 Polish patients.
Nadaj-Pakleza A; Richard P; Lusakowska A; Gajewska J; Jamrozik Z; Kostera-Pruszczyk A; Kwieciński H; Kamińska A
Neurol Neurochir Pol; 2009; 43(2):113-20. PubMed ID: 19484687
[TBL] [Abstract][Full Text] [Related]
20. Animal model of oculopharyngeal muscular dystrophy.
Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
